PHATHOM PHARMACEUTICALS, INC. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
PHATHOM PHARMACEUTICALS, INC. (PHAT) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $18.10 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-07-30
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $18.10M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $20.10M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $18.20M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $18.80M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount as first filed |
|---|---|---|
| 2026-06-30 | $18.10M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $20.10M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $18.20M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $18.80M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $21.20M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $17.10M 10-Q · filed 2025-05-01 | |
| 2024-09-30 | $18.10M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $20.30M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $20.20M 10-Q/A · filed 2024-06-14 | |
| 2023-12-31 | $15.30M 10-K · filed 2025-03-06 | $13.20M 10-K · filed 2024-03-07 |
| 2023-09-30 | $13.90M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $33.20M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $37.30M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $37.30M 10-K · filed 2023-02-28 | |
| 2022-09-30 | $42.40M 10-Q/A · filed 2022-11-09 | |
| 2022-06-30 | $47.90M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $52.30M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $46.60M 10-K · filed 2022-03-01 | |
| 2021-09-30 | $49.40M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $53.00M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $56.50M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $28.20M 10-K · filed 2021-03-30 | |
| 2020-09-30 | $24.70M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $10.60M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $9.00M 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $6.80M 10-K · filed 2020-03-19 | |
| 2019-09-30 | $3.80M 10-Q · filed 2019-11-25 | |
| 2019-06-30 | $59.00K 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |